Sarcopenia and frailty in older patients with diabetes mellitus Hiroyuki Umegaki Department of Community Healthcare & Geriatrics, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
Sarcopenia is defined as age-associated loss of muscle mass and function, and is frequently accompanied by diabetes mellitus (DM) in older adults. Some of the mechanisms of the development of sarcopenia including insulin resistance, chronic inflammation and mitochondrial dysfunction are also associated with the pathogenesis of DM. Sarcopenia provides the basis for frailty, which is a state that is highly vulnerable to stressors, and can lead to disability, dependency and mortality, and older DM patients are often in a state of frailty. Given the background of an increasing number of older DM patients, the screening and early detection of sarcopenia/frailty and appropriate intervention would be expected to improve the prognosis and quality of life in older patients. Geriatr Gerontol Int 2016; 16: 293–299. Keywords: dementia, diabetes mellitus, frailty, sarcopenia.
The prevalence of diabetes mellitus (DM) is increasing worldwide. With the advancement of the management of DM and of DM comorbidity, life expectancy in DM patients has been extended mainly as a result of decreased cardiovascular mortality, which has led to an increase in the number of older individuals with DM.1 This increase in the number of patients has led to the development of many research interests in this population, which has shown that older DM patients are often in a state of sarcopenia and/or frailty. Sarcopenia and frailty are associated with one another and often coexist. Sarcopenia/frailty has been shown to have a poor prognosis; however, recent research achievements suggest that it is a potentially reversible or preventable condition. It is, therefore, urgent that more research evidence be accumulated to ensure healthier lives for older DM patients. The current review addresses the issue of sarcopenia/ frailty in older DM patients.
What is sarcopenia? Aging is accompanied by a loss of skeletal muscle mass, power and function. The age-associated change of skel-
Accepted for publication 16 October 2015. Correspondence: Dr Hiroyuki Umegaki, MD, PhD, Department of Community Healthcare and Geriatrics, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan. Email: [email protected]
etal muscle is called sarcopenia. Sarcopenia is a progressive and generalized loss of skeletal muscle mass and strength. Skeletal muscle is essential to maintaining our postures and making movements, while it also plays a major role in glucose metabolism. In addition, recent studies have shown that skeletal muscle works as an endocrine organ that secretes myokines.2 Therefore, it has been shown that sarcopenia is associated with several age-related mobility disorders, falls and fractures, impaired activities of daily living scores, disabilities, loss of independence, and increased risk of death.3 The decline of muscle strength does not solely result from the reduction of muscle mass, but also from the reduction of muscle quality. Muscle mass measurement is not sufficient for the screening of sarcopenia; measurements of muscle performance, such as muscle power or gait speed, would be required to identify sarcopenia. An algorithm for identifying sarcopenia was suggested by the European Working Group on Sarcopenia in Older People. It recommends starting the screening of sarcopenia with gait speed measurement, followed by measuring grip strength or muscle mass.3 Modifications for Asian populations were recently proposed by the Asian Working Group for Sarcopenia.4
Mechanism of development of sarcopenia in older adults The underlying mechanisms of the development of sarcopenia are likely multifactorial and largely remain to doi: 10.1111/ggi.12688
be elucidated; however, significant progress has been made in this field, and has shed light on the mechanism of age-associated skeletal muscle functional decline and volume decrease. Skeletal muscle is a dynamic organ that keeps turning over through constant synthesis and degradation. The turning over of the proteins in the skeletal muscle is regulated through complicated mechanisms. Insulin resistance increases with aging, and is involved in several underlying mechanisms of sarcopenia induction.5 Insulin is a catabolic hormone, which stimulates protein synthesis including that in muscle. Defects in insulin signaling can lead to reduced muscle synthesis.6 Chronic inflammation, probably along with oxidative stress, has been shown to increase with aging, and is considered to be involved in the mechanism of sarcopenia.7 Mitochondria dysfunction leads to less efficient energy production, and increased production of reactive oxygen species is also considered to be involved.8,9 Age-related sex hormone reduction10 or other hormonal changes including growth hormone and insulin-like growth factor 1 have been reported to be associated with sarcopenia.11 It is also suggested that the functional decline of neuromuscular junction with aging might also be involved.12 Neuronal loss and impaired re-innervation might be associated with the development of sarcopenia.
Sarcopenia and frailty Recently, the concept of frailty syndrome has attracted a great deal of research interest. It has been generally agreed that frailty is a state in which one is highly vulnerable to stressors that lead to disability, dependency and mortality with decreased physical reserves. Frailty has been defined as a predisability condition, and the validity of the framework of the frailty phenotype, which was developed by Fried et al., has been well established. This framework contains five components: exhaustion, physical inactivity, muscle weakness, slow walking speed and weight loss.13 Two of these components, muscle weakness and slow walking speed, are parts of the sarcopenia phenotype. Because sarcopenia is a major component of frailty, sarcopenia and frailty often overlap. Many older adults with frailty have sarcopenia, and some individuals with sarcopenia show frailty syndrome. Frailty is associated with a number of adverse health outcomes, such as disability, falls, hospitalization, institutionalization and mortality. Frailty, however, is a reversible condition. Frequent transitions among frail, prefrail and non-frail conditions have been reported.14 Therefore, frailty is a good target in the prevention of disability states. So far, interventions with nutrition including amino acids and exercise have been carried 294 |
out in the treatment of sarcopenia/frailty; however, the effects of these interventions are relatively limited, and more efficacious measures are warranted.15
It was shown that risk factors for diabetes also predict frailty.38 Low physical activity and a lack of daily consumption of fruits and vegetables were considered the risks for developing DM, and were associated with subsequent frailty. This could suggest that frailty and DM have some common pathogenetic basis. Repeated hypoglycemia is often seen in older diabetics, and the negative impact of repeated hospitalization as a result of hypoglycemia might be responsible for frailty in older patients with DM.39 Older patients with DM are often taking many kinds of medication.40 Polypharmacy is associated with adverse drug reactions through drug–drug interactions, and can contribute to adverse health outcomes.41
Adverse outcomes associated with sarcopenia/frailty in older DM patients Falls Sarcopenia is reportedly a risk for falls,42 while DM is an established risk for falls.43,44 A Japanese study showed that lower walking speed, which is one of the manifestations of sarcopenia/frailty, was associated with falls in type 2 DM patients.45 Elderly diabetic patients with the sarcopenia/frailty phenotype and their caregivers should be educated regarding the standard pharmacological and non-pharmacological methods of prevention of falls and fracture, and these methods should be implemented.46
Depression DM is a risk factor for depression.47,48 The vascular depression as a result of the cerebrovascular burden that is associated with vascular risk factors including DM is reportedly associated with frailty.49 Frailty is manifested not only physically, but also mentally. Some evidence has shown that frailty increases the risk of depression.50,51 Furthermore, subjects with frailty tend to have less frequent social communications and poor networks, which are also risk factors for depression.
disease pathology.54,55 Both cross-sectional and longitudinal studies have shown that frailty is associated with cognitive impairment,56,57 whereas cognitive impairment might be one of the phenotypes of frailty.58
Hypoglycemia Loss of appetite and weight reduction, which are often seen in frail elderly individuals, are risk factors for hypoglycemia. Severe hypoglycemia often leads to hospitalization in older people. Repeated hospital admission could lead to the deterioration of a patient’s general condition and lead to frailty.39 Cognitive impairment, which often coexists with frailty syndrome, has a bidirectional association with hypoglycemia. Cognitive impairment is a risk for hypoglycemia, and hypoglycemia induces cognitive impairment.59 In the treatment of frail diabetic older individuals, the prevention and avoidance of hypoglycemia should always be considered a priority.
Risk of cardiovascular and non-cardiovascular mortality Older DM patients, especially those with a long disease history, often have cardiovascular comorbidity. Frailty is an established risk factor for cardiovascular disease incidence and death in patients with cardiovascular disease, whereas cardiovascular comorbidity is a risk for frailty.60,61 A recent report from China showed that frailty is a risk factor independent from other classic vascular risk factors for adverse health outcomes including death in older adults with type 2 DM.62
Treatment and management of older DM patients with sarcopenia/frailty The mechanism of development of sarcopenia/frailty includes insulin resistance, hyperglycemia and inflammation, and these factors are also included in the pathophysiologies associated with DM. The treatment for these factors in patients with DM, especially in its early stages, could contribute to preventing the development of sarcopenia/frailty in later life stages in older DM patients. So far, however, there is little evidence regarding the effects of the prevention of sarcopenia/frailty through pharmacological antidiabetic treatments. Future research and accumulation of evidence on this issue is warranted. Non-pharmacological intervention has potential efficacy in the treatment of sarcopenia/ frailty.
Exercise Resistance training has beneficial effects on sarcopenia in an older general population,63 and has also been | 295
shown to be effective to counteract the exacerbation of the loss of muscle mass and performance in older type 2 DM patients.64 The effect of aerobic exercise on sarcopenia/frailty in older DM patients has not been investigated extensively yet; however, the effects of the combination of resistance and aerobic training on glycemic control were established in older DM patients;65 therefore, the combination of resistance and aerobic exercise would be appropriate in this population when contraindications do not exist, and might have beneficial effects in terms of the prevention of sarcopenia/frailty.
Nutrition The protein needs with aging study group recommended 1.0–1.2 g/kg bodyweight of dietary protein intake for adults aged 65 years and older to keep and regain lean body mass and function.66 A study showed that 1 g protein/kg bodyweight helped maintain muscle strength in older diabetic women.67 Although an appropriate diet for good blood glucose maintenance is important in patients with DM, malnutrition should be avoided in older subjects, especially in frailty or prefrailty conditions.
Association of antidiabetic agents and sarcopenia/frailty An association between antidiabetic agents and sarcopenia/frailty has been reported; however, our knowledge regarding this issue is limited. More data should be accumulated.
Insulin Insulin stimulates protein synthesis, and is expected to have the potential to prevent sarcopenia in patients with type 2 DM; however, the beneficial effects of insulin on sarcopenia have not been proven in clinical settings.
Glitazones Some studies have shown that Peroxisome ProliferatorActivated Receptor gamma agonists, which are insulin sensitizers, have some beneficial effects on muscle performance in older diabetes patients.68–70 The accumulation of more evidence is warranted.
Biganides Metformin could increase lean body mass and decrease fat.71 Animal studies have, however, suggested that metformin might have some negative impacts on mitochondrial function in skeletal muscle.72,73 296 |
Sulfonylureas and glinides Sulfonylureas and glinides, which are ATP-sensitive potassium channel blockers, stimulate insulin release in pancreatic beta cells. Some reports have shown that the drugs in this class might be associated with muscle atrophy.74
Incretins Incretins have been shown to have beneficial effects on muscle.75 Dipeptidyl Peptidase-4 inhibitors and Glucagon-like peptide-1 agonists might be expected to have antisarcopenic effects. However, no clinical evidence of this has been accumulated so far.
SGLT2 inhibitors A newly developed class of antidiabetic drug, sodium glucose transporter 2 inhibitors, has recently been introduced in clinical settings. Currently, no evidence has been accumulated regarding the effects of this class of drug on muscle; however, the acceleration of catabolic effects by expelling a certain amount of calories through urine excretion in frail older adults should be considered.
Type 1 DM and sarcopenia/frailty The present review has dealt mainly with type 2 DM. However, because of recent advancements in the treatment of type 1 DM, the life expectancy of individuals with type 1 DM has been extended, and more old elderly type 1 DM patients are appearing in clinical settings.76 Because the main manifestation of type 1 DM is the impairment of insulin secretion, which is closely associated with protein synthesis, type 1 DM has been reported to result in muscle atrophy beginning at a relatively young age.77 So far, scarce data have been accumulated regarding sarcopenia/frailty in older type 1 DM patients.
relevance of all medications for patients whose backgrounds include poor prognosis and a high risk of adverse drug reactions in order to avoid polypharmacy. DM patients with sarcopenia/frailty are also at high risk of functional decline. Therefore, the identification of sarcopenia/frailty prompts a comprehensive geriatric assessment to identify problems and establish effective interventions to help patients and caregivers, and possibly to improve the patient’s functional status and quality of life. To improve the patient’s sarcopenia/frailty status or to prevent the onset of sarcopenia/frailty, the prescription of appropriate and individualized exercise and adequate nutritional intake should also be considered.
Conclusion Sarcopenia and frailty are mutually associated with one another and often coexist with DM. Sarcopenia/frailty in older DM patients is a marker of poor prognosis. The screening for and early detection of sarcopenia/frailty and the use of appropriate intervention would be expected to improve the prognosis and quality of life in older patients. More research should be carried out to help overcome sarcopenia/frailty in older DM patients, who represent a rapidly increasing population.
Disclosure statement The author declares no conflict of interest.
8 Figueiredo PA, Mota MP, Appell HJ, Duarte JA. The role of mitochondria in aging of skeletal muscle. Biogerontology 2008; 9: 67–84. 9 Calvani R, Joseph AM, Adhihetty PJ et al. Mitochondrial pathways in sarcopenia of aging and disuse muscle atrophy. Biol Chem 2013; 394: 393–414. 10 Horstman AM, Dillon EL, Urban RJ, Sheffield-Moore M. The role of androgens and estrogens on healthy aging and longevity. J Gerontol A Biol Sci Med Sci 2012; 67: 1140–1152. 11 Goldspink G, Harridge SD. Growth factors and muscle ageing. Exp Gerontol 2004; 39: 1433–1438. 12 Gonzalez-Freire M, de Cabo R, Studenski SA, Ferrucci L. The neuromuscular junction: aging at the crossroad between nerves and muscle. Front Aging Neurosci. 2014; 6: 208. 13 Morley JE, Vellas B, van Kan GA et al. Frailty consensus: a call to action. J Am Med Dir Assoc 2013; 14: 392–397. 14 Gill TM, Gahbauer EA, Allore HG, Han L. Transitions between frailty states among community-living older persons. Arch Intern Med 2006; 166: 418–423. 15 Bibas L, Levi M, Bendayan M, Mullie L, Forman DE, Afilalo J. Therapeutic interventions for frail elderly patients: part I. Published randomized trials. Prog Cardiovasc Dis 2014; 57: 134–143. 16 Wong E, Backholer K, Gearon E et al. Diabetes and risk of physical disability in adults: a systematic review and metaanalysis. Lancet Diabetes Endocrinol 2013; 1: 106–114. 17 Kim TN, Park MS, Yang SJ et al. Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: the Korean Sarcopenic Obesity Study (KSOS). Diabetes Care 2010; 33: 1497–1499. 18 Ottenbacher KJ, Graham JE, Al Snih S et al. Mexican Americans and frailty: findings from the Hispanic established populations epidemiologic studies of the elderly. Am J Public Health 2009; 99: 673–679. 19 Hubbard RE, Andrew MK, Fallah N, Rockwood K. Comparison of the prognostic importance of diagnosed diabetes, co-morbidity and frailty in older people. Diabet Med 2010; 27: 603–606. 20 Cacciatore F, Testa G, Galizia G et al. Clinical frailty and long-term mortality in elderly subjects with diabetes. Acta Diabetol 2013; 50: 251–260. 21 Saum KU, Dieffenbach AK, Müller H, Holleczek B, Hauer K, Brenner H. Frailty prevalence and 10-year survival in community-dwelling older adults: results from the ESTHER cohort study. Eur J Epidemiol 2014; 29: 171–179. 22 Jung HW, Kim SW, Ahn S et al. Prevalence and outcomes of frailty in Korean elderly population: comparisons of a multidimensional frailty index with two phenotype models. PLoS ONE 2014; 9: e87958. 23 Lee JS, Auyeung TW, Leung J, Kwok T, Leung PC, Woo J. Physical frailty in older adults is associated with metabolic and atherosclerotic risk factors and cognitive impairment independent of muscle mass. J Nutr Health Aging 2011; 15: 857–862. 24 Leenders M, Verdijk LB, van der Hoeven L et al. Patients with type 2 diabetes show a greater decline in muscle mass, muscle strength, and functional capacity with aging. J Am Med Dir Assoc 2013; 14: 585–592. 25 Andreassen CS, Jakobsen J, Ringgaard S, Ejskjaer N, Andersen H. Accelerated atrophy of lower leg and foot muscles – a follow-up study of long-term diabetic polyneuropathy using magnetic resonance imaging (MRI). Diabetologia 2009; 52: 1182–1191. doi: 10.1007/s00125009-1320-0. 26 Andersen H, Nielsen S, Mogensem CE, Jakobsen J. Muscle strength in type 2 diabetes. Diabetes 2004; 53: 1543–1548.
H Umegaki 27 Andersen H, Poulsen PL, Mogensen CE, Jakobsen J. Isokinetic muscle strength in long-term IDDM patients in relation to diabetic complications. Diabetes 1996; 45: 440– 445. 28 Allen MD, Choi IH, Kimpinski K, Doherty TJ, Rice CL. Motor unit loss and weakness in association with diabetic neuropathy in humans. Muscle Nerve 2013; 48: 298–300. doi: 10.1002/mus.23792. 29 Andreassen CS, Jakobsen J, Andersen H. Muscle weakness. A progressive late complication in diabetic distal symmetric polyneuropathy. Diabetes 2006; 55: 806–812. 30 Rabøl R, Larsen S, Højberg PM et al. Regional anatomic differences in skeletal muscle mitochondrial respiration in type 2 diabetes and obesity. J Clin Endocrinol Metab 2010; 95: 857–863. doi: 10.1210/jc.2009-1844. 31 Ramamurthy B, Höök P, Jones AD, Larsson L. Changes in myosin structure and function in response to glycation. FASEB J 2001; 15: 2415–2422. 32 Kalyani RR, Metter EJ, Egan J, Golden SH, Ferrucci L. Hyperglycemia predicts persistently lower muscle strength with aging. Diabetes Care 2015; 38: 82–90. 33 Cruz NG, Sousa LP, Sousa MO, Pietrani NT, Fernandes AP, Gomes KB. The linkage between inflammation and Type 2 diabetes mellitus. Diabetes Res Clin Pract 2013; 99: 85–92. 34 Jo E, Lee SR, Park BS, Kim JS. Potential mechanisms underlying the role of chronic inflammation in age-related muscle wasting. Aging Clin Exp Res 2012; 24: 412–422. 35 García-Esquinas E, Graciani A, Guallar-Castillón P, López-García E, Rodríguez-Mañas L, Rodríguez-Artalejo F. Diabetes and risk of frailty and its potential mechanisms: a prospective cohort study of older adults. J Am Med Dir Assoc 2015; 16: 748–754. doi: 10.1016/j.jamda.2015.04 .008; pii: S1525-8610(15)00296-0. 36 Park SW, Goodpaster BH, Strotmeyer ES et al. Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes 2006; 55: 1813–1818. 37 Sergi G, Veronese N, Fontana L et al. Pre-frailty and risk of cardiovascular disease in elderly men and women: the pro.v.a. study. J Am Coll Cardiol 2015; 65: 976–983. 38 Bouillon K, Kivimäki M, Hamer M et al. Diabetes risk factors, diabetes risk algorithms, and the prediction of future frailty: the Whitehall II prospective cohort study. J Am Med Dir Assoc 2013; 14: 851.e1–851.e6. 39 Abdelhafiz AH, Rodríguez-Mañas L, Morley JE, Sinclair AJ. Hypoglycemia in older people – a less well recognized risk factor for frailty. Aging Dis 2015; 6: 156– 167. 40 Noale M, Veronese N, Cavallo Perin P et al. Polypharmacy in elderly patients with type 2 diabetes receiving oral antidiabetic treatment. Acta Diabetol 2015 doi: 10.1007/s00592015-0790-4. 41 Herr M, Robine JM, Pinot J, Arvieu JJ, Ankri J. Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old people. Pharmacoepidemiol Drug Saf 2015; 24: 637–646. 42 Landi F, Liperoti R, Russo A et al. Sarcopenia as a risk factor for falls in elderly individuals: results from the ilSIRENTE study. Clin Nutr 2012; 31: 652–658. 43 Maurer MS, Burcham J, Cheng H. Diabetes mellitus is associated with an increased risk of falls in elderly residents of a long-term care facility. J Gerontol A Biol Sci Med Sci 2005; 60: 1157–1162. 44 Yau RK, Strotmeyer ES, Resnick HE et al. Diabetes and risk of hospitalized fall injury among older adults. Diabetes Care 2013; 36: 3985–3991.
Sarcopenia and frailty in DM 63 Peterson MD, Rhea MR, Sen A, Gordon PM. Resistance exercise for muscular strength in older adults: a metaanalysis. Ageing Res Rev 2010; 9: 226–237. 64 Cadore EL, Izquierdo M. Exercise interventions in polypathological aging patients that coexist with diabetes mellitus: improving functional status and quality of life. Age (Dordr) 2015; 37: 9800. 65 Tan S, Li W, Wang J. Effects of six months of combined aerobic and resistance training for elderly patients with a long history of type 2 diabetes. J Sports Sci Med. 2012; 11: 495–501. 66 Bauer J, Biolo G, Cederholm T et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc 2013; 14: 542–559. 67 Rahi B, Morais JA, Gaudreau P, Payette H, Shatenstein B. Energy and protein intakes and their association with a decline in functional capacity among diabetic older adults from the NuAge cohort. Eur J Nutr 2015; PMID: 26179475. 68 Lee CG, Boyko EJ, Barrett-Connor E et al. Insulin sensitizers may attenuate lean mass loss in older men with diabetes. Diabetes Care 2011; 34: 2381–2386. 69 Mensink M, Hesselink MK, Russell AP, Schaart G, Sels JP, Schrauwen P. Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/ delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus. Int J Obes (Lond) 2007; 31: 1302–1310. 70 Skov V, Glintborg D, Knudsen S et al. Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome. PLoS ONE 2008; 3: e2466.
71 Rodríguez-Moctezuma JR, Robles-López G, LópezCarmona JM, Gutiérrez-Rosas MJ. Effects of metformin on the body composition in subjects with risk factors for type 2 diabetes. Diabetes Obes Metab 2005; 7: 189–192. 72 Wessels B, Ciapaite J, van den Broek NM, Nicolay K, Prompers JJ. Metformin impairs mitochondrial function in skeletal muscle of both lean and diabetic rats in a dosedependent manner. PLoS ONE 2014; 9: e100525. 73 Kane DA, Anderson EJ, Price JW 3rd et al. Metformin selectively attenuates mitochondrial H2O2 emission without affecting respiratory capacity in skeletal muscle of obese rats. Free Radic Biol Med 2010; 49: 1082–1087. 74 Mele A, Calzolaro S, Cannone G, Cetrone M, Conte D, Tricarico D. Database search of spontaneous reports and pharmacological investigations on the sulfonylureas and glinides-induced atrophy in skeletal muscle. Pharmacol Res Perspect 2014; 2: e00028. doi: 10.1002/prp2.28. 75 Abdulla H, Phillips B, Smith K, Wilkinson D, Atherton PJ, Idris I. Physiological mechanisms of action of incretin and insulin in regulating skeletal muscle metabolism. Curr Diabetes Rev 2014; 10: 231–237. 76 Livingstone SJ, Levin D, Looker HC et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008– 2010. JAMA 2015; 313: 37–44. 77 Krause MP, Riddell MC, Hawke TJ. Effects of type 1 diabetes mellitus on skeletal muscle: clinical observations and physiological mechanisms. Pediatr Diabetes 2011; 12 (4 Pt 1): 345–364. 78 Han Cho N, Colagiuri S, Distiller L et al. International Diabetes Federation Global Guideline for Managing Older People with Type 2 Diabetes. Brussels: International Diabetes Federation, 2013.
Populations are aging and the prevalence of diabetes mellitus is increasing tremendously. The number of older people with diabetes is increasing unexpectedly. Aging and diabetes are both risk factors for functional disability. Thus, increasing number
Food preservation technologies and medical advances in the past 50 years have contributed to safeguarding the health and prolonging the lives of individuals worldwide. However, living longer does not automatically equate with being healthy, living in
Sarcopenia describes a loss of muscle mass and resultant decrease in strength, mobility, and function that can be quantified by CT. We hypothesized that sarcopenia and related frailty characteristics are related to discharge disposition after blunt t
Sarcopenia and frailty are common geriatric syndromes and are associated with adverse health outcome and impaired health-related quality of life. Co-occurrences of these two syndromes with age-related neurological diseases are potentially high but no
Population aging is rapidly accelerating worldwide; however, longer life expectancy is not the only public health goal. Indeed, extended lifetime involves maintaining function and the capacity of living independently. Sarcopenia and physical frailty
In the coming decades, the population of older adults with type 2 diabetes mellitus is expected to grow substantially. Understanding the clinical course of diabetes in this population is critical for establishing evidence-based clinical practice reco
Sarcopenia and frailty often co-exist and both have physical function impairment as a core component. Yet despite the urgency of the problem, the development of pharmaceutical therapies for sarcopenia and frailty has lagged, in part because of the la